R
Rachelle S. Doody
Researcher at Hoffmann-La Roche
Publications - 277
Citations - 32934
Rachelle S. Doody is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Dementia & Alzheimer's disease. The author has an hindex of 69, co-authored 247 publications receiving 29981 citations. Previous affiliations of Rachelle S. Doody include Baylor College of Medicine & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Current concepts in mild cognitive impairment.
Ronald C. Petersen,Rachelle S. Doody,Alexander Kurz,Richard C. Mohs,John C. Morris,Peter V. Rabins,Karen Ritchie,Martin N. Rossor,Leon J. Thal,Bengt Winblad +9 more
TL;DR: A group of experts on aging and MCI from around the world in the fields of neurology, psychiatry, geriatrics, neuropsychology, neuroimaging, neuropathology, clinical trials, and ethics was convened to summarize the current state of the field of MCI.
Journal ArticleDOI
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Ronald C. Petersen,Ronald G. Thomas,Michael Grundman,David A. Bennett,Rachelle S. Doody,Steven H. Ferris,Douglas Galasko,Shelia Jin,Jeffrey Kaye,Allan I. Levey,Eric Pfeiffer,Mary Sano,Christopher H. van Dyck,Leon J. Thal +13 more
TL;DR: Vitamin E had no benefit in patients with mild cognitive impairment and donepezil therapy was associated with a lower rate of progression to Alzheimer's disease during the first 12 months of treatment, a finding supported by the secondary outcome measures.
Journal ArticleDOI
Memantine in Moderate-to-Severe Alzheimer's Disease
Barry Reisberg,Rachelle S. Doody,Albrecht Stöffler,Frederick A. Schmitt,Steven H. Ferris,Hans Jörg Möbius +5 more
TL;DR: Antiglutamatergic treatment reduced clinical deterioration in moderate-to-severe Alzheimer's disease, a phase associated with distress for patients and burden on caregivers, for which other treatments are not available.
Journal ArticleDOI
Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology
Rachelle S. Doody,James C. Stevens,Cornelia Beck,Richard Dubinsky,Jeffrey Kaye,Lisa P. Gwyther,Richard C. Mohs,Leon J. Thal,Peter J. Whitehouse,Steven T. DeKosky,Jeffrey L. Cummings +10 more
TL;DR: Dementia criteria for dementia have improved since the 1994 practice parameter, and further research is needed to improve clinical definitions of dementia and its subtypes, as well as to determine the utility of various instruments of neuroimaging, biomarkers, and genetic testing in increasing diagnostic accuracy.
Journal ArticleDOI
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
TL;DR: The data indicate that donepezil is a well-tolerated drug that improves cognition and global function in patients with mild to moderate AD.